Schizophrenia: from dopamine to glutamate and back.

• The first part of the present review describes the exciting journey of dopamine stabilizers, starting in the early eighties with the development of the partial dopamine agonist (-)-3-PPP of phenylpiperidine structure, via various compounds with aminotetraline structure with preferential autoreceptor antagonist properties, and then back again to phenylpiperidine compounds carrying substituents on the aromatic ring that transformed them from partial dopamine agonists to partial dopamine receptor antagonists, such as OSU6162. OSU6162 was brought to the clinic and has in preliminary trials showed antidyskinetic and antipsychotic efficacy. The second part of this review describes results from a hypoglutamatergia mouse model for cognitive symptoms of schizophrenia, where we have tested traditional neuroleptics, new generation antipsychotics with marked 5-HT2 vs dopamine D2 receptor blockade as well as a dopamine stabilizer belonging to the partial dopamine receptor antagonist category.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Fysiologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Physiology (hsv//eng)

Nyckelord

Animals

Antipsychotic Agents

therapeutic use

Disease Models

Animal

Dopamine

metabolism

Dopamine Agonists

metabolism

therapeutic use

Dopamine Antagonists

therapeutic use

Excitatory Amino Acid Antagonists

pharmacology

therapeutic use

Glutamic Acid

metabolism

Mice

Piperazines

therapeutic use

Piperidines

chemistry

therapeutic use

Quinolones

therapeutic use

Schizophrenia

drug therapy

metabolism

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)